Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Paul Bolno, a director of Invivyd, Inc. (IVVD), was granted a stock option on 09/22/2025 to buy 100,000 shares of common stock at an exercise price of $1.22 per share. The option expires on 09/21/2035. The grant vests over three years: one-third vests on the first anniversary of the grant and the remainder vests in equal monthly installments (1/36th) thereafter, subject to continuous service through each vesting date. Following the grant, the reporting person beneficially owns 100,000 option shares, held directly. The Form 4 was filed with a signature dated 09/24/2025 by an attorney-in-fact.
Invivyd Form 3 filed for Paul Bolno reports that Paul Bolno, identified as a director of Invivyd, Inc. (IVVD), has filed an initial Section 16 statement and discloses no securities beneficially owned as of the event date. The form lists the reporting person's address as c/o Invivyd, Inc., 209 Church Street, New Haven, CT. The filing is signed by an attorney-in-fact for Mr. Bolno and includes a Power of Attorney reference as an exhibit.
Invivyd, Inc. appointed Paul B. Bolno, M.D. to its Board of Directors and Compensation Committee, effective September 22, 2025, filling a vacancy created by the same-day resignation of director Christine Akinc, who left without any disagreement on company matters. Dr. Bolno will receive an annual cash retainer of $40,000 for Board service and $5,000 for Compensation Committee service.
He was also granted a nonqualified option to acquire 100,000 shares of common stock, vesting over three years from September 22, 2025, and exercisable for 10 years at the closing market price on the grant date under the 2021 Equity Incentive Plan. Separately, Nasdaq notified Invivyd on September 22, 2025 that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, and the matter is now closed.
Janus Henderson Group plc reported beneficial ownership of 24,271,759 shares of Invivyd, Inc. common stock, representing 11.6% of the class. The filing states Janus Henderson has shared voting and shared dispositive power over those 24,271,759 shares and no sole voting or dispositive power. The Schedule 13G identifies the reporting person as Janus Henderson Group plc (organized in Jersey) and lists indirect subsidiaries JHIUS, JHIUKL and JHIAIFML as registered investment advisers that furnished investment advice to Managed Portfolios. The statement includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is signed by Kristin Mariani, Head of North America Compliance, CCO, dated 09/08/2025.
RA Capital Management, Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund report collective beneficial ownership of 21,338,288 shares of Invivyd, Inc. (CUSIP 00534A102), representing approximately 9.99% of the outstanding common stock as of August 22, 2025. The Fund directly holds 17,119,096 shares plus pre-funded warrants exercisable for up to 21,342,442 shares, but the Pre-Funded Warrants include a Beneficial Ownership Blocker that prevents exercises that would raise ownership above 9.99%, limiting current exercisable holdings to 21,338,288 shares. RA Capital serves as investment adviser and has sole voting and dispositive power over the Funds holdings; Dr. Kolchinsky and Mr. Shah are identified as controlling persons and signed the filing on August 29, 2025.
Point72 group disclosed a passive 13G stake in Invivyd, Inc. The filing shows Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen beneficially own 16,730,467 shares, representing 8.0% of Invivyd's outstanding common stock based on 209,377,291 shares outstanding following the issuer's August 22, 2025 underwritten offering. The reported shares are held through Point72 Associates, LLC, with shared voting and dispositive power and no sole voting or dispositive power reported. The filing is submitted on a joint basis and states the position is not intended to influence control of the issuer.
Amendment No. 4 to a Schedule 13D reports that M28 Capital Management LP and Marc Elia hold common stock and director options in Invivyd, Inc. The filing states the reporting persons now beneficially own a combined 9,248,250 shares through shared voting and dispositive power attributed to M28 and an aggregate 9,548,250 shares when including Mr. Elia's 300,000 director stock options. Those amounts represent 4.4% (M28) and 4.6% (Elia) of the outstanding common stock, calculated using 209,377,291 shares outstanding per Invivyd's August 22, 2025 prospectus and press release. The amendment is an "exit filing" because, due solely to a change in the number of shares outstanding, the reporting persons no longer beneficially own more than 5% and are leaving the Schedule 13D reporting system. The director options were granted for board service; no transactions were effected in the past 60 days per the filing.
Invivyd, Inc. completed an offering of common stock and pre-funded warrants, selling pre-funded warrants convertible into 21,342,442 shares and common shares at a public price of $0.52 per share. The pre-funded warrants had a public price of $0.5199 each, reflecting the $0.0001 per share exercise price difference.
The underwriting agreement included a 30-day option to purchase up to 14,423,076 additional shares at the same price, and that option was exercised in full on August 21, 2025, bringing the combined issuance (initial shares plus exercised option) to 35,765,518 shares or the equivalent in pre-funded warrants. These transactions raise capital for the company but increase the number of outstanding shares available to the market, which affects existing shareholders through dilution.
Invivyd, Inc. is offering up to 21,342,442 pre-funded warrants and accompanying common stock at $0.52 per share (pre-funded warrants priced at $0.5199). The offering would raise gross proceeds of approximately $50.0 million (without option) and up to $57.5 million (with option), with underwriting discounts and estimated expenses deducted. Net proceeds are intended to fund development and trials for the investigational antibody VYD2311, R&D for other pipeline programs (RSV, measles), SPEAR Study Group activities on Long COVID/PVS, and general corporate purposes. As-adjusted net tangible book value as of June 30, 2025 would be about $89.3 million or $0.41 per share, producing immediate dilution of $0.11 per share to new investors. The pre-funded warrants likely will not trade on Nasdaq or another exchange and include ownership-based exercise limits (default 4.99% or 9.99% election, adjustable up to 19.99% with notice). The offering is subject to customary lock-up provisions, U.S. and non-U.S. resale restrictions, and tax withholding rules for non-U.S. holders.
Invivyd, Inc. describes regulatory and clinical progress for its COVID-19 monoclonal antibody programs and terms of a securities offering. The company notes PEMGARDA (pemivibart) is authorized for pre-exposure prophylaxis in certain immunocompromised patients under emergency use with restrictions tied to national variant susceptibility thresholds. It reports VYD2311 completed positive Phase 1/2 safety and pharmacokinetic data and that the FDA advised a compact Phase 2/3 trial could support a BLA for prevention of COVID-19 in persons 12 years and older (>=40 kg), subject to agreement on safety database size and final protocol review. The prospectus supplement discloses intended use of proceeds to advance VYD2311 clinical development, other R&D (including RSV and measles), SPEAR Study Group work on Long COVID/PVS, and general corporate purposes. It also details offering mechanics: lock-up provisions (60 days), at-the-market sales ($39.3 million sold to date, $34.5 million available), registration rights, and various U.S. and non-U.S. tax and resale considerations.